Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

siponimod

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

- PMLiVE

Democrats regain control of House in mid-terms

Biotech and pharma share price indexes have climbed since the news broke

- PMLiVE

Pfizer claims rapid FDA nod for Lorbrena

Green light is latest in a string of cancer drug approvals

- PMLiVE

Novartis culls pipeline to focus on most transformative science

Anti-infectives among areas hit by streamlining

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

Pharma: in search of the sustainable ‘win win’ with the NHS

Fiona Bride on how Novartis is responding to new models of care

- PMLiVE

Novartis gains label boost for Cosentyx

Updated label allows dosing flexibility of up to 300mg

- PMLiVE

Novartis claims a rare win at ESMO for PI3K inhibitor class

Analysts predict drug could hit $1.5bn annual sales

- PMLiVE

Novartis buys cancer specialist Endocyte for $2.1bn

Acquisition includes 'universal' CAR-T platform

- PMLiVE

US says medicine ads should include list prices

Hopes the proposal will encourage lower prescription drug prices

- PMLiVE

Tackling a formidable foe

Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis

- PMLiVE

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

Panel voted 10 to 3 in favour of the treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links